Life Sciences Voice
Life Sciences Voice | The leading resource for life sciences industry executives.
- Website
- lifescivoice.com · all feeds from this site
- Feed URL
https://lifescivoice.com/feed/
Read it in your FeedListing reader
Or add to: Feedly Inoreader Raw feed
Latest posts
-
Top 10 Digital Capabilities Separating Industry Leaders
Executive Summary Digital maturity is becoming a competitive differentiator across the pharmaceutical and biotechnology industries. While many organizations invest in artificial intelligence, cloud platforms, analytics, and automation, their ability to translate these…
-
Astellas wagers $1.3 billion on Audax’s preclinical effort to end decades of IL-12 problems
Financial Terms and Partnership Scope Astellas has agreed to up to $285 million in upfront and option payments to get an opportunity to license the preclinical immuno-oncology program from Audax Biosciences. The deal, which includes up to $1.05 billion in milestones, gives…
-
Vera Health Raises $28.5 Million to Expand Clinical AI Search Platform
Vera Health, a clinical artificial intelligence search engine, has secured $28.5 million in Series A funding to expand its platform. The funding round was led by Threshold Ventures, with participation from Optum Ventures, Mantis VC, and SV Angel. Existing investors Y Combinator…
-
Novartis Reports Late-Stage Trial Setbacks for Del-Desiran and Pelacarsen
Novartis reported late-stage clinical trial failures for two experimental medicines in September, including del-desiran, which was being developed for myotonic dystrophy, and pelacarsen, a drug being tested for heart disease. The setbacks resulted in substantial charges for the…
-
Top 10 Metrics Clinical Operations Leaders Should Track
Executive Summary Clinical operations leaders must balance trial speed, cost, quality, participant safety, and operational reliability. As studies become more complex and involve multiple countries, sites, vendors, and digital systems, traditional milestone reporting often…
-
Menarini’s Stemline Signs Huge Deal With Georgiamine For Preclincal Cancer Drug
Georgiamune, a Maryland-based biotechnology company focused on immunology, has licensed an experimental cancer treatment to Stemline Therapeutics, a subsidiary of Menarini Group, in an agreement valued at up to $1.1 billion. Under the deal announced October 22, Stemline will pay…
-
Roivant Sets Sights on Humira as Lisraya Performs Well in Eye Disease Study
Following Lisraya’s first regulatory approval, Roivant and its subsidiary Priovant are seeking to expand the drug’s reach into additional immune-mediated conditions. The companies have reported positive results from two Phase 3 trials of brepocitinib, a once-daily inhibitor of…
-
BMS Reports Positive Phase 3 Results for Iza-Bren in Lung and Breast Cancer
Bristol Myers Squibb (BMS) has reported positive results from two phase 3 trials of izalontamab brengitecan (iza-bren), a bispecific antibody-drug conjugate (ADC), in patients with lung and breast cancer. Conducted in China by the drug’s original developer, Sichuan Biokin…
-
BioNTech Reports Modest Benefit and Safety Concerns in Phase 3 Breast Cancer Trial
BioNTech and DualityBio have reported topline results from DYNASTY-Breast02, a global phase 3 clinical trial evaluating trastuzumab pamirtecan (t-pam) in patients with hormone receptor-positive (HR-positive), HER2-low metastatic breast cancer. The study demonstrated a…
-
GSK’s Hepatitis B Drug Gets FDA Green Light
GSK has secured U.S. approval for bepirovirsen, an antisense oligonucleotide licensed from Ionis Pharmaceuticals, marking a milestone in the treatment of chronic hepatitis B. Marketed as Hibsago, the medicine introduces an antisense-based approach to the infection and offers…